Clinical Trial Update: A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Thymoglobulin® to prevent cardiac allograft vasculopathy in heart transplant recipients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Allograft Vasculopathy

Drugs mentioned

• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Cardiac Allograft Vasculopathy | Phase 3 | Status: WITHDRAWN